These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 33031955)

  • 1. TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol.
    Piccirillo MC; Ascierto P; Atripaldi L; Cascella M; Costantini M; Dolci G; Facciolongo N; Fraganza F; Marata A; Massari M; Montesarchio V; Mussini C; Negri EA; Parrella R; Popoli P; Botti G; Arenare L; Chiodini P; Gallo C; Salvarani C; Perrone F
    Contemp Clin Trials; 2020 Nov; 98():106165. PubMed ID: 33031955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial.
    Soin AS; Kumar K; Choudhary NS; Sharma P; Mehta Y; Kataria S; Govil D; Deswal V; Chaudhry D; Singh PK; Gupta A; Agarwal V; Kumar S; Sangle SA; Chawla R; Narreddy S; Pandit R; Mishra V; Goel M; Ramanan AV
    Lancet Respir Med; 2021 May; 9(5):511-521. PubMed ID: 33676589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lescure FX; Honda H; Fowler RA; Lazar JS; Shi G; Wung P; Patel N; Hagino O;
    Lancet Respir Med; 2021 May; 9(5):522-532. PubMed ID: 33676590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
    Perrone F; Piccirillo MC; Ascierto PA; Salvarani C; Parrella R; Marata AM; Popoli P; Ferraris L; Marrocco-Trischitta MM; Ripamonti D; Binda F; Bonfanti P; Squillace N; Castelli F; Muiesan ML; Lichtner M; Calzetti C; Salerno ND; Atripaldi L; Cascella M; Costantini M; Dolci G; Facciolongo NC; Fraganza F; Massari M; Montesarchio V; Mussini C; Negri EA; Botti G; Cardone C; Gargiulo P; Gravina A; Schettino C; Arenare L; Chiodini P; Gallo C;
    J Transl Med; 2020 Oct; 18(1):405. PubMed ID: 33087150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
    Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
    BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
    Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
    J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan.
    Chiodini P; Arenare L; Piccirillo MC; Perrone F; Gallo C
    Contemp Clin Trials Commun; 2020 Dec; 20():100665. PubMed ID: 33043164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
    Strohbehn GW; Heiss BL; Rouhani SJ; Trujillo JA; Yu J; Kacew AJ; Higgs EF; Bloodworth JC; Cabanov A; Wright RC; Koziol AK; Weiss A; Danahey K; Karrison TG; Edens CC; Bauer Ventura I; Pettit NN; Patel BK; Pisano J; Strek ME; Gajewski TF; Ratain MJ; Reid PD
    Clin Pharmacol Ther; 2021 Mar; 109(3):688-696. PubMed ID: 33210302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
    Tenda ED; Andrian S; Albert S; Asaf MM; Pitoyo CW; Setiati S; Subekti I
    Acta Med Indones; 2021 Jul; 53(3):319-325. PubMed ID: 34611072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.